User login
Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).
Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.
Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.
Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.
Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943
Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).
Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.
Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.
Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.
Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943
Key clinical point: Etanercept was safe and effective with low rates of adverse events and led to better clinical outcomes in children with juvenile psoriatic arthritis (JPsA).
Major finding: The overall incidence of adverse events of special interest and serious adverse events were low and included 3 cases of uveitis (incidence rate [IR]/100 person-years 0.55; 95% CI 0.18-1.69), 1 of neuropathy (IR/100 person-years 0.18; 95% CI 0.03-1.29), and 1 of malignancy (IR/100 person-years 0.13; 95% CI 0.02-0.90). The American College of Rheumatology provisional criteria for inactive disease were achieved by 51.9% and 43.8% of patients at 6- and 12-month follow-ups.
Study details: This study included 226 patients with JPsA (aged ≥2 to <18 years) who received etanercept.
Disclosures: This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. S Stryker and D Collier declared being employees of and owning stocks in Amgen. SJ Balevic and T Beukelman declared receiving grants or research support, honoraria, or consulting fees or participating in data safety monitoring boards for various sources. The other authors declared no conflicts of interest.
Source: Correll CK et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023;9:e002943 (May 25). doi: 10.1136/rmdopen-2022-002943